MARKET

ACHFF

ACHFF

Arch Biopartners
OTCMQB
0.405
NaN%
Closed 14:59 04/01 EDT
OPEN
--
PREV CLOSE
0.405
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
1.410
52 WEEK LOW
0.356
MARKET CAP
27.11M
P/E (TTM)
-13.5940
1D
5D
1M
3M
1Y
5Y
1D
Arch Biopartners closes CAD 0.6 million private placement of common shares
Reuters · 5d ago
ARCH BIOPARTNERS CLOSES NON-BROKERED PRIVATE PLACEMENT
Reuters · 5d ago
Arch Biopartners announces CAD 0.6 million private placement of common shares
Reuters · 03/30 10:04
ARCH BIOPARTNERS ARRANGES NON-BROKERED PRIVATE PLACEMENT
Reuters · 03/30 10:03
Arch Biopartners signs clinical trial agreement with Fraser Health Authority for Phase II LSALT peptide trial
Reuters · 03/24 13:13
ARCH BIOPARTNERS AND THE FRASER HEALTH AUTHORITY ENTER INTO A CLINICAL TRIAL AGREEMENT FOR THE PHASE II CARDIAC SURGERY-ASSOCIATED AKI TRIAL
Reuters · 03/24 13:13
St. Michael’s Hospital begins dosing patients in Arch Biopartners’ 240-patient Phase II LSALT peptide trial
Reuters · 03/20 11:17
ARCH BIOPARTNERS ANNOUNCES ST. MICHAEL’S HOSPITAL COMMENCES PATIENT DOSING IN THE PHASE II CS-AKI TRIAL OF LSALT PEPTIDE
Reuters · 03/20 11:05
More
About ACHFF
Arch Biopartners Inc. is a therapeutic biotech company developing novel drugs for acute and chronic kidney diseases. The Company is advancing an integrated pipeline that includes new treatments targeting inflammation and toxin-induced kidney injury. Its programs include a pre-clinical chronic kidney disease platform targeting interleukin-32 (IL-32), LSALT peptide, a dipeptidase-1 (DPEP1) inhibitor in Phase II for preventing cardiac surgery-associated acute kidney injury, and cilastatin, a repurposed drug in Phase II for preventing toxin-induced kidney damage. These assets represent distinct, mechanism-based approaches to treating and preventing common causes of kidney damage. Together, they target serious unmet needs in kidney care across both chronic and acute indications, affecting millions of patients worldwide. Its LSALT Peptide and cilastatin, are being developed to target kidney injury caused by inflammation or toxins respectively, which are both significant unmet medical needs.

Webull offers Arch Biopartners Inc stock information, including OTCMQB: ACHFF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACHFF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ACHFF stock methods without spending real money on the virtual paper trading platform.